Cargando…
MYC DNA Methylation in Prostate Tumor Tissue is Associated with Gleason Score
Increasing evidence suggests a role of epigenetic mechanisms at chromosome 8q24, an important cancer genetic susceptibility region, in prostate cancer. We investigated whether MYC DNA methylation at 8q24 (six CpG sites from exon 3 to the 3′ UTR) in prostate tumor was associated with tumor aggressive...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823928/ https://www.ncbi.nlm.nih.gov/pubmed/33374332 http://dx.doi.org/10.3390/genes12010012 |
_version_ | 1783639953403543552 |
---|---|
author | Barry, Kathryn Hughes Mohanty, Kareshma Erickson, Patricia A. Wang, Difei Shi, Jianxin Rose, Gary Cellini, Ashley Clark, Kimberly Ambulos, Nicholas Yin, Jing Yan, Liying Poulin, Matthew Meyer, Ann Zhang, Yuji Bentzen, Søren M. Burke, Allen Hussain, Arif Berndt, Sonja I. |
author_facet | Barry, Kathryn Hughes Mohanty, Kareshma Erickson, Patricia A. Wang, Difei Shi, Jianxin Rose, Gary Cellini, Ashley Clark, Kimberly Ambulos, Nicholas Yin, Jing Yan, Liying Poulin, Matthew Meyer, Ann Zhang, Yuji Bentzen, Søren M. Burke, Allen Hussain, Arif Berndt, Sonja I. |
author_sort | Barry, Kathryn Hughes |
collection | PubMed |
description | Increasing evidence suggests a role of epigenetic mechanisms at chromosome 8q24, an important cancer genetic susceptibility region, in prostate cancer. We investigated whether MYC DNA methylation at 8q24 (six CpG sites from exon 3 to the 3′ UTR) in prostate tumor was associated with tumor aggressiveness (based on Gleason score, GS), and we incorporated RNA expression data to investigate the function. We accessed radical prostatectomy tissue for 50 Caucasian and 50 African American prostate cancer patients at the University of Maryland Medical Center, selecting an equal number of GS 6 and GS 7 cases per group. MYC DNA methylation was lower in tumor than paired normal prostate tissue for all six CpG sites (median difference: −14.74 to −0.20 percentage points), and we observed similar results for two nearby sites in The Cancer Genome Atlas (p < 0.0001). We observed significantly lower methylation for more aggressive (GS 7) than less aggressive (GS 6) tumors for three exon 3 sites (for CpG 212 (chr8:128753145), GS 6 median = 89.7%; GS 7 median = 85.8%; p-value = 9.4 × 10(−4)). MYC DNA methylation was not associated with MYC expression, but was inversely associated with PRNCR1 expression after multiple comparison adjustment (q-value = 0.04). Findings suggest that prostate tumor MYC exon 3 hypomethylation is associated with increased aggressiveness. |
format | Online Article Text |
id | pubmed-7823928 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-78239282021-01-24 MYC DNA Methylation in Prostate Tumor Tissue is Associated with Gleason Score Barry, Kathryn Hughes Mohanty, Kareshma Erickson, Patricia A. Wang, Difei Shi, Jianxin Rose, Gary Cellini, Ashley Clark, Kimberly Ambulos, Nicholas Yin, Jing Yan, Liying Poulin, Matthew Meyer, Ann Zhang, Yuji Bentzen, Søren M. Burke, Allen Hussain, Arif Berndt, Sonja I. Genes (Basel) Article Increasing evidence suggests a role of epigenetic mechanisms at chromosome 8q24, an important cancer genetic susceptibility region, in prostate cancer. We investigated whether MYC DNA methylation at 8q24 (six CpG sites from exon 3 to the 3′ UTR) in prostate tumor was associated with tumor aggressiveness (based on Gleason score, GS), and we incorporated RNA expression data to investigate the function. We accessed radical prostatectomy tissue for 50 Caucasian and 50 African American prostate cancer patients at the University of Maryland Medical Center, selecting an equal number of GS 6 and GS 7 cases per group. MYC DNA methylation was lower in tumor than paired normal prostate tissue for all six CpG sites (median difference: −14.74 to −0.20 percentage points), and we observed similar results for two nearby sites in The Cancer Genome Atlas (p < 0.0001). We observed significantly lower methylation for more aggressive (GS 7) than less aggressive (GS 6) tumors for three exon 3 sites (for CpG 212 (chr8:128753145), GS 6 median = 89.7%; GS 7 median = 85.8%; p-value = 9.4 × 10(−4)). MYC DNA methylation was not associated with MYC expression, but was inversely associated with PRNCR1 expression after multiple comparison adjustment (q-value = 0.04). Findings suggest that prostate tumor MYC exon 3 hypomethylation is associated with increased aggressiveness. MDPI 2020-12-24 /pmc/articles/PMC7823928/ /pubmed/33374332 http://dx.doi.org/10.3390/genes12010012 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Barry, Kathryn Hughes Mohanty, Kareshma Erickson, Patricia A. Wang, Difei Shi, Jianxin Rose, Gary Cellini, Ashley Clark, Kimberly Ambulos, Nicholas Yin, Jing Yan, Liying Poulin, Matthew Meyer, Ann Zhang, Yuji Bentzen, Søren M. Burke, Allen Hussain, Arif Berndt, Sonja I. MYC DNA Methylation in Prostate Tumor Tissue is Associated with Gleason Score |
title | MYC DNA Methylation in Prostate Tumor Tissue is Associated with Gleason Score |
title_full | MYC DNA Methylation in Prostate Tumor Tissue is Associated with Gleason Score |
title_fullStr | MYC DNA Methylation in Prostate Tumor Tissue is Associated with Gleason Score |
title_full_unstemmed | MYC DNA Methylation in Prostate Tumor Tissue is Associated with Gleason Score |
title_short | MYC DNA Methylation in Prostate Tumor Tissue is Associated with Gleason Score |
title_sort | myc dna methylation in prostate tumor tissue is associated with gleason score |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823928/ https://www.ncbi.nlm.nih.gov/pubmed/33374332 http://dx.doi.org/10.3390/genes12010012 |
work_keys_str_mv | AT barrykathrynhughes mycdnamethylationinprostatetumortissueisassociatedwithgleasonscore AT mohantykareshma mycdnamethylationinprostatetumortissueisassociatedwithgleasonscore AT ericksonpatriciaa mycdnamethylationinprostatetumortissueisassociatedwithgleasonscore AT wangdifei mycdnamethylationinprostatetumortissueisassociatedwithgleasonscore AT shijianxin mycdnamethylationinprostatetumortissueisassociatedwithgleasonscore AT rosegary mycdnamethylationinprostatetumortissueisassociatedwithgleasonscore AT celliniashley mycdnamethylationinprostatetumortissueisassociatedwithgleasonscore AT clarkkimberly mycdnamethylationinprostatetumortissueisassociatedwithgleasonscore AT ambulosnicholas mycdnamethylationinprostatetumortissueisassociatedwithgleasonscore AT yinjing mycdnamethylationinprostatetumortissueisassociatedwithgleasonscore AT yanliying mycdnamethylationinprostatetumortissueisassociatedwithgleasonscore AT poulinmatthew mycdnamethylationinprostatetumortissueisassociatedwithgleasonscore AT meyerann mycdnamethylationinprostatetumortissueisassociatedwithgleasonscore AT zhangyuji mycdnamethylationinprostatetumortissueisassociatedwithgleasonscore AT bentzensørenm mycdnamethylationinprostatetumortissueisassociatedwithgleasonscore AT burkeallen mycdnamethylationinprostatetumortissueisassociatedwithgleasonscore AT hussainarif mycdnamethylationinprostatetumortissueisassociatedwithgleasonscore AT berndtsonjai mycdnamethylationinprostatetumortissueisassociatedwithgleasonscore |